Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia

Fig. 4

CAR.CD123-NK cells show a strong anti-leukaemia activity against the most relevant AML haematopoietic maturation subsets. A Percentage of CD38+CD34 (dotted bar), CD38+CD34+ (light grey bar) and CD38CD34+(white bar) cells obtained from BM samples of AML #1, AML #2, AML#3 and AML#4 were analysed by flow cytometry at thawing. B Percentage of CD123+ cells in the different haematopoietic maturation subsets, namely CD38+CD34 (dotted bar), CD38+CD34+ (light grey bar) and CD38CD34+(white bar) analysed at thawing of AML #1, AML #2, AML#3 and AML#4 BM samples (analysis performed before the in vitro culture of the cells). C AML #1, (D) AML #2, (E) AML#3 and (F) AML#4 BM cells have been independently analysed for the residual percentage of total CD38+CD34, CD38+CD34+ and CD38CD34+ cells (on the left) and for the residual percentage of CD123+ cells (on the right panel) after 6-day culture of leukaemic cells alone (black bars), leukaemic cells with NT-NK cells (grey bars) or with CAR.CD123-NK cells (black line bars) at the E:Tratio of 1:1

Back to article page